Borthakur G, Odenike O, Aldoss I, Rizzieri DA, et al. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. Cancer 2021 May 2. doi: 10.1002/cncr.33590.
PMID: 33934351